STTK Shattuck Labs Inc.

41.75
-0.26  -1%
Previous Close 42.01
Open 41.72
52 Week Low 17.51
52 Week High 59.5699
Market Cap $1,742,821,895
Shares 41,744,237
Float 34,401,712
Enterprise Value $1,589,097,988
Volume 63,951
Av. Daily Volume 181,847
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SL-172154
Ovarian Cancer
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences.

    Presentation Details
    Conference: Cowen 41st Annual Health Care Conference
    Format: Ovarian Cancer Panel discussion
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
    Date: March 2, 2021
    Time: 12:50 p.m. EST
    Webcast Link: The panel discussion will be available live to conference attendees

    Conference: Oppenheimer 31st Annual…

    AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences.

    Presentation Details

    Conference: Cowen 41st Annual Health Care Conference

    Format: Ovarian Cancer Panel discussion

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: March 2, 2021

    Time: 12:50 p.m. EST

    Webcast Link: The panel discussion will be available live to conference attendees

    Conference: Oppenheimer 31st Annual Healthcare Conference

    Presenter: Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

    Date: March 16, 2021

    Time: 11:20 a.m. EST

    Webcast Link: Available Here

    The live webcast of the Oppenheimer presentation will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.





    Primary Logo

    View Full Article Hide Full Article
  2. AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi's 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

    Presentation Details
    Conference: Citi 2021 Virtual Immuno-Oncology Day
    Format: Group meeting with Andrew Baum and covering analyst Mohit Bansal
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy
    Date: February…

    AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi's 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

    Presentation Details

    Conference: Citi 2021 Virtual Immuno-Oncology Day

    Format: Group meeting with Andrew Baum and covering analyst Mohit Bansal

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

    Date: February 17, 2021

    Time: 12:00 p.m. EST

    Webcast Link: Available Here

    A live webcast will be available at the Events & Presentations section of the Company's website.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

     

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

     



    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021.

    Presentation Details
    Conference: H.C. Wainwright BioConnect 2021 Conference
    Presenter: Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy
    Date: January 11, 2021
    Time: 6:00 a.m. EST
    Webcast Link: Available Here

    The presentation will be available on-demand through the H.C. Wainwright conference portal…

    AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021.

    Presentation Details

    Conference: H.C. Wainwright BioConnect 2021 Conference

    Presenter: Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

    Date: January 11, 2021

    Time: 6:00 a.m. EST

    Webcast Link: Available Here

    The presentation will be available on-demand through the H.C. Wainwright conference portal and available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.



    Primary Logo

    View Full Article Hide Full Article
  4. AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.

    Presentation Details
    Conference: 39th Annual J.P. Morgan Healthcare Conference
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
    Date: January 14, 2021
    Time: 5:20 p.m. EST
    Webcast Link: Available Here

    The live webcast of the presentation will be available on the Events & Presentations section…

    AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.

    Presentation Details

    Conference: 39th Annual J.P. Morgan Healthcare Conference

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: January 14, 2021

    Time: 5:20 p.m. EST

    Webcast Link: Available Here

    The live webcast of the presentation will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 30 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.



    Primary Logo

    View Full Article Hide Full Article
  5. AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will be added to the Russell 2000® and 3000® Indexes effective December 21, 2020, following Russell's quarterly additions of select initial public offerings.

    "We are incredibly pleased to be included in the Russell 2000® and Russell 3000® Indexes," said Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy. "This milestone reflects the potential that investors see in Shattuck. Importantly, it…

    AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will be added to the Russell 2000® and 3000® Indexes effective December 21, 2020, following Russell's quarterly additions of select initial public offerings.

    "We are incredibly pleased to be included in the Russell 2000® and Russell 3000® Indexes," said Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy. "This milestone reflects the potential that investors see in Shattuck. Importantly, it increases our visibility in the investment community while broadening our institutional shareholder base."

    Russell indexes are part of FTSE Russell, a leading global index provider. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.



    Primary Logo

    View Full Article Hide Full Article
View All Shattuck Labs Inc. News